<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">rpcardio</journal-id><journal-title-group><journal-title xml:lang="en">Rational Pharmacotherapy in Cardiology</journal-title><trans-title-group xml:lang="ru"><trans-title>Рациональная Фармакотерапия в Кардиологии</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1819-6446</issn><issn pub-type="epub">2225-3653</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20996/1819-6446-2024-3004</article-id><article-id custom-type="edn" pub-id-type="custom">LTCIUU</article-id><article-id custom-type="elpub" pub-id-type="custom">rpcardio-3004</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>NOTES FROM PRACTICE</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЙ ОПЫТ</subject></subj-group></article-categories><title-group><article-title>Effectiveness of different treatment regimens of enhanced external counterpulsation in patients with stable coronary artery disease complicated by heart failure</article-title><trans-title-group xml:lang="ru"><trans-title>Эффективность различных режимов усиленной наружной контрпульсации у пациентов со стабильной ишемической болезнью сердца, осложненной сердечной недостаточностью</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3391-0193</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лишута</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Lishuta</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лишута Алексей Сергеевич </p><p>Москва</p></bio><bio xml:lang="en"><p>Alexey S. Lishuta</p><p>Moscow</p></bio><email xlink:type="simple">alexeylish@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1172-1116</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Слепова</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Slepova</surname><given-names>O. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Слепова Ольга Александровна </p><p>Москва</p></bio><bio xml:lang="en"><p>Olga A. Slepova</p><p>Moscow</p></bio><email xlink:type="simple">slepova_o_a@staff.sechenov.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8907-8370</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Николаева</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Nikolaeva</surname><given-names>N. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Николаева Надежда Андреевна </p><p>Москва</p></bio><bio xml:lang="en"><p>Nadezhda A. Nikolaeva</p><p>Moscow</p></bio><email xlink:type="simple">nikolaeva_n_a@staff.sechenov.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8843-2374</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хабарова</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Khabarova</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Хабарова Наталья Владимировна </p><p>Москва</p></bio><bio xml:lang="en"><p>Natalia V. Khabarova</p><p>Moscow</p></bio><email xlink:type="simple">khabarova_n_v@staff.sechenov.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6675-7557</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Привалова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Privalova</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Привалова Елена Витальевна </p><p>Москва</p></bio><bio xml:lang="en"><p>Elena V. Privalova</p><p>Moscow</p><p> </p></bio><email xlink:type="simple">privalova_e_v@staff.sechenov.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3014-6129</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Беленков</surname><given-names>Ю. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Belenkov</surname><given-names>Yu. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Беленков Юрий Никитич </p><p>Москва</p></bio><bio xml:lang="en"><p>Yuri N. Belenkov</p><p>Moscow</p></bio><email xlink:type="simple">belenkov_yu_n@staff.sechenov.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I. M. Sechenov First Moscow State Medical University (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>02</day><month>02</month><year>2024</year></pub-date><volume>20</volume><issue>1</issue><fpage>35</fpage><lpage>45</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Lishuta A.S., Slepova O.A., Nikolaeva N.A., Khabarova N.V., Privalova E.V., Belenkov Y.N., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Лишута А.С., Слепова О.А., Николаева Н.А., Хабарова Н.В., Привалова Е.В., Беленков Ю.Н.</copyright-holder><copyright-holder xml:lang="en">Lishuta A.S., Slepova O.A., Nikolaeva N.A., Khabarova N.V., Privalova E.V., Belenkov Y.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpcardio.online/jour/article/view/3004">https://www.rpcardio.online/jour/article/view/3004</self-uri><abstract><sec><title>Aim</title><p>Aim. To study the effect of various therapy regimens with enhanced external counterpulsation (EECP) on exercise tolerance, quality of life, indices of structural and functional state of cardiovascular system in patients with stable coronary artery disease (CAD) complicated by chronic heart failure (CHF).</p></sec><sec><title>Material and methods</title><p>Material and methods. The study included patients with stable CAD complicated by CHF with reduced and intermediate left ventricular ejection fraction (LVEF) from the randomized EXCEL trial (NCT05913778; n=120) and additionally patients with similar inclusion and exclusion criteria (n=90) who were randomized into groups with different EECP treatment regimens for 12 months: Group 1 (n=40): course of 35 hour-long procedures; Group 2 (n=40): course of 35 hourlong procedures every 6 months; Group 3 (n=30): course of 20 hour-long procedures then constantly 1 hour per week; Group 4 (n=30): constantly 2 hours per week; Group 5 (n=30): course of 20 hour-long procedures then constantly 2 hours per week; Group 0 (placebo ; n=40): course of 35 hour-long procedures with compression pressure 80 mm Hg. All patients at baseline and after 12 months were assessed for clinical status, quality of life (MLHFQ, SF-36), NT-proBNP levels, LVEF, as well as exercise tolerance (6-minute walk test; 6MWT) initially, after 3, 6, 9 and 12 months. Correlation analysis and risk assessment of adverse events (combined endpoint — combination of cases of adverse cardiovascular events, deaths, hospitalizations for CHF, new-onset of atrial fibrillation, diabetes, decreased renal function) was performed.</p></sec><sec><title>Results</title><p>Results. Treatment effectiveness had positive correlation with EECP duration (r(S)=0,670; p&lt;0,001) and treatment regimen (r(S)=0,620; p&lt;0,001). The maximum effect (changes in NT-proBNP levels, LVEF, clinical status, quality of life) was noted in the combined and constant regimen groups (5, 4, 2). The increase of 6WMTdistance was 6,6% in group 0, 24,9% in group 1, 44,5% in group 2, 31,8% in group 3, 49,1% in group 4, 58,6% in group 5. The proportion of patients with an increase in 6WMT-distance &gt;20% after 12 months was 7,7%, 72,5%, 97,5%, 76,7%, 90%, 100%, respectively. Cumulative event-free survival was highest in groups 5, 4, and 2 (0,97, 0,93, and 0,86, respectively), and the risk of developing combined endpoint in these groups was minimal (0,035, 0,075, and 0,150, respectively).</p></sec><sec><title>Conclusion</title><p>Conclusion. The effect of EECP treatment in patients with coronary artery disease complicated by CHF depended on the EECP hours and regimen. Alternative EECP regimens (with more treatments spread evenly over the year) in addition to optimal medical therapy may improve the management of these patients.</p></sec><sec><title> </title><p> </p></sec></abstract><trans-abstract xml:lang="ru"><sec><title>Цель</title><p>Цель. Изучить влияние различных режимов терапии усиленной наружной контрпульсацией (УНКП) на толерантность к физической нагрузке, качество жизни, показатели структурно-функционального состояния сердечно-сосудистой системы у пациентов со стабильной ишемической болезнью сердца (ИБС), осложненной хронической сердечной недостаточностью (ХСН).</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В исследование включены пациенты со стабильной ИБС, осложненной ХСН со сниженной и промежуточной фракцией выброса левого желудочка (ФВ ЛЖ) из рандомизированного исследования EXCEL (NCT05913778; n=120) и дополнительно пациенты с аналогичными критериями включения и исключения (n=90), которые были рандомизированы в группы с различными режимами УНКП в течение 12 мес. (группа 1 (n=40): курс 35 часовых процедур; группа 2 (n=40): курс 35 часовых процедур каждые 6 мес.; группа 3 (n=30): курс 20 часовых процедур затем постоянно 1 час в неделю; группа 4 (n=30): постоянно по 2 ч в неделю; группа 5 (n=30): курс 20 часовых процедур затем постоянно по 2 часа в неделю; группа 0 (плацебо; n=40): курс 35 часовых процедур с давлением компрессии 80 мм рт.ст.). Всем пациентам исходно и через 12 мес. проводились оценка клинического статуса, качества жизни (MLHFQ, SF-36), уровней NT-proBNP, ФВ ЛЖ, а также толерантности к физической нагрузке (тест 6-минутной ходьбы; 6МХТ) исходно, через 3, 6, 9 и 12 мес. Проведены корреляционный анализ и оценка риска развития неблагоприятных событий (комбинированной конечной точки (ККТ: комбинация случаев неблагоприятных исходов, госпитализаций по поводу ХСН, развития новых случаев фибрилляции предсердий, сахарного диабета (СД), снижения функции почек)).</p></sec><sec><title>Результаты</title><p>Результаты. Эффективность лечения прямо коррелировала с количеством часов УНКП (r(S)=0,670; p&lt;0,001) и режимом лечения (r(S)=0,620; p&lt;0,001). Максимальный эффект отмечен в группах комбинированного и постоянного режимов (динамика уровней NT-proBNP, ФВ ЛЖ, клинического статуса, качества жизни). Увеличение дистанции в 6МХТ составило 6,6% в группе 0, 24,9% в группе 1, 44,5% в группе 2, 31,8% в группе 3, 49,1% в группе 4, 58,6% в группе 5. Доля пациентов с увеличением дистанции в 6МХТ &gt;20% через 12 мес составила соответственно 7,7%, 72,5%, 97,5%, 76,7%, 90%, 100%. Кумулятивная бессобытийная выживаемость была максимальной в группах 5, 4 и 3 (97%, 93% и 86% соответственно), а кумулятивный риск развития ККТ в этих группах минимальный (3,5%, 7,5% и 15%, соответственно).</p></sec><sec><title>Заключение</title><p>Заключение. Эффект лечения УНКП пациентов с ИБС, осложненной ХСН, зависел от количества часов и режима лечения УНКП. Альтернативные режимы УНКП (с бóльшим количеством процедур и их равномерным распределением в течение года) в дополнение к оптимальной медикаментозной терапии могут повысить эффективность ведения таких больных.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>усиленная наружная контрпульсация</kwd><kwd>ишемическая болезнь сердца</kwd><kwd>хроническая сердечная недостаточность</kwd><kwd>режим лечения</kwd><kwd>толерантность к нагрузке</kwd><kwd>качество жизни</kwd></kwd-group><kwd-group xml:lang="en"><kwd>enhanced external counterpulsation</kwd><kwd>coronary heart disease</kwd><kwd>chronic heart failure</kwd><kwd>treatment regimen</kwd><kwd>exercise tolerance</kwd><kwd>quality of life</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование выполнено при поддержке Сеченовского Университета</funding-statement><funding-statement xml:lang="en">The study was supported by Sechenov University</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Tsao CW, Aday AW, Almarzooq ZI, et al.; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association. Circulation. 2023;147(8):e93-e621. DOI:10.1161/CIR.0000000000001123.</mixed-citation><mixed-citation xml:lang="en">Tsao CW, Aday AW, Almarzooq ZI, et al.; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association. Circulation. 2023;147(8):e93-e621. DOI:10.1161/CIR.0000000000001123.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020;22(8):1342-356. DOI:10.1002/ejhf.1858.</mixed-citation><mixed-citation xml:lang="en">Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020;22(8):1342-356. DOI:10.1002/ejhf.1858.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Niimi N, Sawano M, Ikemura N, et al. Applicability and Eligibility of the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) for Patients who Underwent Revasculariza - tion with Percutaneous Coronary Intervention. J Clin Med. 2020;9(9):2889. DOI:10.3390/jcm9092889.</mixed-citation><mixed-citation xml:lang="en">Niimi N, Sawano M, Ikemura N, et al. Applicability and Eligibility of the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) for Patients who Underwent Revasculariza - tion with Percutaneous Coronary Intervention. J Clin Med. 2020;9(9):2889. DOI:10.3390/jcm9092889.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Wu E, Desta L, Broström A, Mårtensson J. Effectiveness of Enhanced External Counterpulsation Treatment on Symptom Burden, Medication Profile, Physical Capacity, Cardiac Anxiety, and Health-Related Quality of Life in Patients With Refractory Angina Pectoris. J Cardiovasc Nurs. 2020;35(4):375-385. DOI:10.1097/JCN.0000000000000638.</mixed-citation><mixed-citation xml:lang="en">Wu E, Desta L, Broström A, Mårtensson J. Effectiveness of Enhanced External Counterpulsation Treatment on Symptom Burden, Medication Profile, Physical Capacity, Cardiac Anxiety, and Health-Related Quality of Life in Patients With Refractory Angina Pectoris. J Cardiovasc Nurs. 2020;35(4):375-385. DOI:10.1097/JCN.0000000000000638.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Arora RR, Chou TM, Jain D, et al. The multicenter study of enhanced external counterpulsation (MUST-EECP): effect of EECP on exercise-induced myocardial ischemia and anginal episodes. J Am Coll Cardiol. 1999;33(7):1833-40. DOI:10.1016/s0735-1097(99)00140-0.</mixed-citation><mixed-citation xml:lang="en">Arora RR, Chou TM, Jain D, et al. The multicenter study of enhanced external counterpulsation (MUST-EECP): effect of EECP on exercise-induced myocardial ischemia and anginal episodes. J Am Coll Cardiol. 1999;33(7):1833-40. DOI:10.1016/s0735-1097(99)00140-0.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Шмалий А. В., Чернышев А. В., Хечумян А. Ф. и др. Использование усиленной наружной контрпульсации при комплексной медицинской реабилитации стабильных форм ишемической болезни сердца у пациентов, постоянно проживающих в условиях влажных субтропиков. Вестник Восстановительной Медицины. 2022;21(3):96-107. DOI:10.38025/2078-1962-2022-21-3-96-107.</mixed-citation><mixed-citation xml:lang="en">Shmaliy AV, Chernyshev AV, Khechumyan AF, et al. The use of enhanced external counterpulsation in complex medical rehabilitation of stable forms of coronary heart disease in patients permanently living in humid subtropical conditions. Bulletin of Restorative Medicine. 2022;21(3):96-107 (In Russ) DOI:10.38025/2078-1962-2022-21-3-96-107.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Князева Т.А., Никифорова Т.И. Усиленная наружная контрпульсация в реабилитации пациентов после кардиохирургических вмешательств. Вопросы Курортологии, Физиотерапии и Лечебной Физической Культуры. 2020;97(6-2):53.</mixed-citation><mixed-citation xml:lang="en">Knyazeva TA, Nikiforova TI. Enhanced external counterpulsation in the rehabilitation of patients after cardiac surgery. Questions of Resortology, Physiotherapy and Therapeutic Physical Culture. 2020;97(6-2):53 (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Шашенков И.В., Горбунова М.В., Бабак С.Л. Влияние наружной контрпульсации на фракцию выброса левого желудочка и дистанцию теста шестиминутной ходьбы у больных с проявлениями хронической коронарогенной сердечной недостаточности после перенесённого COVID-19: результаты однолетнего наблюдения. Терапия. 2023;9(S3):456-7. DOI:10.18565/therapy.2023.3suppl.456-457.</mixed-citation><mixed-citation xml:lang="en">Shashenkov IV, Gorbunova MV, Babak SL. The effect of external counterpulsation on left ventricular ejection fraction and six-minute walk test distance in patients with manifestations of chronic coronary heart failure after COVID-19: results of a one-year follow-up. Therapy. 2023;9(S3):456-7 (In Russ.) DOI:10.18565/therapy.2023.3suppl.456-457.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Lin S, Xiao-Ming W, Gui-Fu W. Expert consensus on the clinical application of enhanced external counterpulsation in elderly people (2019). Aging Med (Milton). 2020;3(1):16-24. DOI:10.1002/agm2.12097.</mixed-citation><mixed-citation xml:lang="en">Lin S, Xiao-Ming W, Gui-Fu W. Expert consensus on the clinical application of enhanced external counterpulsation in elderly people (2019). Aging Med (Milton). 2020;3(1):16-24. DOI:10.1002/agm2.12097.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Караганов К.С., Слепова О.А., Лишута А.С., и др. Среднесрочное влияние усиленной наружной контрпульсации на структурно-функциональные показатели сосудов у пациентов с ишемической болезнью сердца. Рациональная Фармакотерапия в Кардиологии. 2021;17(4):557-63. DOI:10.20996/1819-6446-2021-08-03.</mixed-citation><mixed-citation xml:lang="en">Karaganov K. S., Slepova O.A., Lishuta A. S., et al. Medium-term Effects of Enhanced External Counterpulsation in the Structural and Functional Parameters of Blood Vessels in Patients with Coronary Artery Disease. Rational Pharmacotherapy in Cardiology. 2021;17(4):557-63 (In Russ.) DOI:10.20996/1819-6446-2021-08-03.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Беленков Ю.Н., Лишута А.С., Слепова О.А., и др. Возможности усиленной наружной контрпульсации в реабилитации пациентов со стабильной ишемической болезнью сердца, осложненной сердечной недостаточностью: данные исследования EXCEL. Кардиология. 2024;64(1):14-24. DOI:10.18087/cardio.2024.1.n2615.</mixed-citation><mixed-citation xml:lang="en">Belenkov YuN, Lishuta AS, Slepova OA, et al. Possibilities of enhanced external counterpulsation in the rehabilitation of patients with stable coronary heart disease complicated by heart failure: data from the EXCEL study. Kardiologiia. 2024;64(1):14-24. (In Russ.) DOI:10.18087/cardio.2024.1.n2615.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Wu E, Mårtensson J, Desta L, Broström A. Adverse events and their management during enhanced external counterpulsation treatment in patients with refractory angina pectoris: observations from a routine clinical practice. Eur J Cardiovasc Nurs. 2022;21(2):152-160. DOI:10.1093/eurjcn/zvab040.</mixed-citation><mixed-citation xml:lang="en">Wu E, Mårtensson J, Desta L, Broström A. Adverse events and their management during enhanced external counterpulsation treatment in patients with refractory angina pectoris: observations from a routine clinical practice. Eur J Cardiovasc Nurs. 2022;21(2):152-160. DOI:10.1093/eurjcn/zvab040.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Jan R, Khan A, Zahid S, et al. The Effect of Enhanced External Counterpulsation (EECP) on Quality of life in Patient with Coronary Artery Disease not Amenable to PCI or CABG. Cureus. 2020;12(5):e7987. DOI:10.7759/cureus.7987.</mixed-citation><mixed-citation xml:lang="en">Jan R, Khan A, Zahid S, et al. The Effect of Enhanced External Counterpulsation (EECP) on Quality of life in Patient with Coronary Artery Disease not Amenable to PCI or CABG. Cureus. 2020;12(5):e7987. DOI:10.7759/cureus.7987.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Xu L, Cui M, Zhao W. The Effect of EECP on Ischemic Heart Failure: a Systematic Review. Curr Cardiol Rep. 2023;25(10):1291-1298. DOI:10.1007/s11886-023-01943-1.</mixed-citation><mixed-citation xml:lang="en">Xu L, Cui M, Zhao W. The Effect of EECP on Ischemic Heart Failure: a Systematic Review. Curr Cardiol Rep. 2023;25(10):1291-1298. DOI:10.1007/s11886-023-01943-1.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou ZF, Wang DJ, Li XM, et al. Effects of enhanced external counterpulsation on exercise capacity and quality of life in patients with chronic heart failure: A meta-analysis. Medicine (Baltimore). 2021;100(27):e26536. DOI:10.1097/MD.0000000000026536.</mixed-citation><mixed-citation xml:lang="en">Zhou ZF, Wang DJ, Li XM, et al. Effects of enhanced external counterpulsation on exercise capacity and quality of life in patients with chronic heart failure: A meta-analysis. Medicine (Baltimore). 2021;100(27):e26536. DOI:10.1097/MD.0000000000026536.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Coombes JS, Dias KA, Lal R, et al. Efficacy of two doses of external counterpulsation (ECP) on glycemic control in people with type 2 diabetes mellitus: A randomized SHAM-controlled trial. Diabetes Res Clin Pract. 2023;200:110701. DOI:10.1016/j.diabres.2023.110701.</mixed-citation><mixed-citation xml:lang="en">Coombes JS, Dias KA, Lal R, et al. Efficacy of two doses of external counterpulsation (ECP) on glycemic control in people with type 2 diabetes mellitus: A randomized SHAM-controlled trial. Diabetes Res Clin Pract. 2023;200:110701. DOI:10.1016/j.diabres.2023.110701.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Lawson WE, Hui JC, Kennard ED, et al.; International Enhanced External Counterpulsation Patient Registry Investigators. Two-year outcomes in patients with mild refractory angina treated with enhanced external counterpulsation. Clin Cardiol. 2006;29(2):69-73. DOI:10.1002/clc.4960290207.</mixed-citation><mixed-citation xml:lang="en">Lawson WE, Hui JC, Kennard ED, et al.; International Enhanced External Counterpulsation Patient Registry Investigators. Two-year outcomes in patients with mild refractory angina treated with enhanced external counterpulsation. Clin Cardiol. 2006;29(2):69-73. DOI:10.1002/clc.4960290207.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
